Figure 5. RUNX1 loss upregulates IL-3 receptor in HSPCs and leukemia.

(A) Genome tracks of RUNX1 and IgG control ChIP-Seq of mobilized CD34⁺ HSPCs at the IL3RA locus. (B) Representative IL-3RA protein expression on CD34⁺ HDR HSPCs after 6 days of culture (left, in vitro) and from hCD45⁺HDR⁺ cells isolated from transplanted NSGS mice (right, in vivo); n = 3 CB each. (C) Genome tracks of RUNX1 and IgG control ChIP-Seq of mobilized CD34⁺ HSPCs at CSF2RA and CSF3R loci. (D) Representative CD116 (GM-CSFR) and CD114 (G-CSFR) protein expression on CD34⁺ HDR HSPCs after 6 days of culture; n = 3 CB each. (E) IL3RA, (F) CSF2RA, and (G) CSF3R transcript levels in RUNX1wt and RUNX1mut AML from TCGA and BeatAML. Unpaired t test. (F) IL-3RA protein expression on mutation profile–matched RUNX1mut and RUNX1wt Lin^–CD45^lo blasts and CD34⁺CD38^–TIM3⁺CD99⁺ LSCs in primary human AML samples.